The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.

Eva Mm StrijbisPavle RepovicJop MostertJames D BowenBernard Mj UitdehaagGary CutterMarcus Werner Koch

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

We found little consistent change in MSIS-29 and SF-36 over 2 years of follow-up in people with SPMS. Our findings show a disconnect between disability worsening and PROM change in this population. Our findings raise caution about the use of these PROMs as primary outcome measures in SPMS trials and call for a critical reappraisal of the longitudinal use of these measures in SPMS trials.

Keyphrases

multiple sclerosis
patient reported outcomes
mass spectrometry
ms ms
cross sectional
type diabetes
metabolic syndrome
insulin resistance